Development of WRAI’s pan-coronavirus vaccine showed promise
On Dec. 28, 2021, researchers at the Walter Reed Army Institute of Research in Silver Spring, Maryland announced…
On Dec. 28, 2021, researchers at the Walter Reed Army Institute of Research in Silver Spring, Maryland announced…
On Dec. 27, 2021, Moderna announced that the Swiss Federal Government had exercised its option to purchase an…
On Dec. 27, 2021, Moderna announced a revised supply agreement with the government of South Korea for 20…
On Dec. 27, 2021, Sorrento Therapeutics announced that initial testing of COVISTIX on recombinant N proteins demonstrated its…
On Dec. 27, 2021, the U.S. Food and Drug Administration authorized an over-the-counter (OTC) COVID-19 antigen test, the…
Our Heroes and Remembrance illustration has Maurice Ralph Hilleman and John Enders, pioneering developers of common vaccines, and…
On Dec. 24, 2021, Merck and Ridgeback Biotherapeutics announced that Japanï¾’s Ministry of Health, Labor and Welfare had…
On Dec. 24, 2021, Roche announced that the U.S. Food and Drug Administration had granted Emergency Use Authorization…
On Dec. 23, 2021, Novavax and SK bioscience announced the expansion of the companies’ collaboration and license agreements…
On Dec. 23, 2021, Merck and Ridgeback Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) had…
On Dec. 23, 2021, OPKO announced preliminary topline results from its Phase 2 trial with RAYALDEEï¾® to treat…
On Dec. 23, 2021, Pfizer and BioNTech announced that they had submitted longer-term follow-up data from the companiesï¾’…
On Dec. 23, 2021, eight substances were added to the Report on Carcinogens, bringing the total list to…
On Dec. 22, 2021, Merck and Ridgeback Biotherapeutics announced that the United Kingdom Government agreed to purchase an…
On Dec. 22, 2021, Gilead Sciences announced full results from a Phase 3 investigational study evaluating the efficacy…
On Dec. 22, 2021, Cocrystal Pharma announced that in vitro studies demonstrate its oral and intranasal/pulmonary SARS-CoV-2 main…
On Dec. 22, 2021, Novavax announced initial data evaluating the immune response of its COVID-19 vaccine, NVX-CoV2373, against…
On Dec. 22, 2021, Pfizer announced that the U.S. Food and Drug Administration (FDA) had authorized the emergency…
On Dec. 22, 2021, the University of Oxfordï¾’s vaccine manufacturing research team published a pre-print paper demonstrating the…
On Dec. 21, 2021, Novavax announced that the first booster doses of NVX-CoV2373, the company’s recombinant nanoparticle protein-based…
On Oct. 21, 2021, Gilead Sciences announced that the European Commission (EC) had approved a variation to the…
On Dec. 21, 2021, the United States Department of Agricultureï¾’s National Veterinary Services Laboratories announced confirmation of SARS-CoV-2…
On Dec. 21, 2021, the University of Oxford’s vaccine manufacturing research team published a pre-print paper demonstrating the…
On Dec. 20, 2021, Novavax announced that the World Health Organization (WHO) had granted a second Emergency Use…
On Dec. 20, 2021, Novavax announced that the European Commission (EC) had granted Novavax conditional marketing authorization (CMA)…
On Dec. 20, 2021, Pfizer and BioNTech announced an agreement had been reached with the European Commission (EC)…
On Dec. 20, 2021, Moderna announced preliminary neutralizing antibody data against the Omicron variant following the Company’s booster…
On Dec. 20, 2021, Oragenics announced it had extended a licensing and collaboration agreement with the National Research…
On Dec. 17, 2021, Novavax and SK bioscience announced that the World Health Organization (WHO) had granted Emergency…
On Dec. 16, 2021, the Ebola outbreak that erupted in the Democratic Republic of the Congo’s North Kivu…